Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pulse Biosciences (PLSE) EBITDA Margin (2020 - 2025)

Pulse Biosciences (PLSE) has 4 years of EBITDA Margin data on record, last reported at 6603.41% in Q4 2025.

  • For Q4 2025, EBITDA Margin changed N/A year-over-year to 6603.41%; the TTM value through Dec 2025 reached 20794.57%, changed N/A, while the annual FY2025 figure was 20794.57%, N/A changed from the prior year.
  • EBITDA Margin reached 6603.41% in Q4 2025 per PLSE's latest filing, up from 22540.7% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 102188.89% in Q4 2022 and bottomed at 22540.7% in Q3 2025.
  • Average EBITDA Margin over 3 years is 8763.47%, with a median of 2488.15% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: soared 22737346bps in 2021, then tumbled -2023944bps in 2022.
  • A 3-year view of EBITDA Margin shows it stood at 1826.54% in 2021, then surged by 5695bps to 102188.89% in 2022, then plummeted by -106bps to 6603.41% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 6603.41% in Q4 2025, 22540.7% in Q3 2025, and 102188.89% in Q4 2022.